What is the recommended treatment for a patient with multifocal premature atrial contractions (PACs) and premature ventricular contractions (PVCs) presenting as bigeminy and triplets with a burden greater than 30%?

Treatment for High-Burden Multifocal PACs and PVCs with Bigeminy/Triplets (>30%)

For patients with multifocal PACs and PVCs presenting with >30% burden, bigeminy, and triplets, initiate beta-blocker therapy immediately, and strongly consider catheter ablation as primary definitive therapy, particularly if symptoms persist or left ventricular dysfunction develops.

Initial Medical Management

Start with beta-blockers as first-line therapy for both PACs and PVCs 1. The 2017 AHA/ACC/HRS guidelines establish beta-blockers as Class I recommendation for symptomatic outflow tract ventricular arrhythmias 1. In a randomized controlled trial, atenolol significantly decreased both symptom frequency (p=0.03) and PVC count (p=0.001) in patients with mean PVC burden of 21,407 beats per 24 hours 1.

Alternative first-line options include:

• Nondihydropyridine calcium channel blockers (diltiazem or verapamil) - also Class I recommendation for outflow tract VAs 1
• These agents reduce arrhythmias through rate control and direct antiarrhythmic effects 1

Avoid Class I Antiarrhythmics Initially

Class I antiarrhythmic medications (flecainide, propafenone) can be effective but are generally avoided due to concerns for adverse effects and proarrhythmic risk 1. The 2015 ESC guidelines explicitly state that prophylactic antiarrhythmic drugs (other than beta-blockers) are not recommended 2.

When to Escalate to Catheter Ablation

Catheter ablation should be strongly considered as primary therapy in your patient given the >30% burden, even if asymptomatic. Here's the algorithmic approach:

Class I Indications for Ablation (Strongest Evidence):

1. Symptomatic patients with outflow tract VAs where medications are ineffective, not tolerated, or not preferred 1
2. PVC burden ≥10% with unexplained LV dysfunction (PVC-induced cardiomyopathy) 3
3. Multifocal PVCs - despite morphological diversity, these often originate from confined anatomical regions allowing systematic ablation 4

Consider Ablation for Your Patient Because:

• Burden >30% significantly increases cardiomyopathy risk - guidelines suggest considering ablation at >20% burden to prevent PVC-induced cardiomyopathy 3
• Multifocal nature - recent 2026 data shows multifocal septal PVCs respond well to stepwise ablation with 83% achieving ≥80% PVC burden reduction 4
• Bigeminy/triplets pattern - suggests high ectopic burden requiring definitive therapy
• Ablation superior to medical therapy - RCTs demonstrate catheter ablation outperforms antiarrhythmic medications (metoprolol or propafenone) with far lower recurrence rates 1

Ablation Strategy Specifics

For multifocal PVCs, the 2026 study demonstrates:

• Systematic mapping of basal septal LV ostium to posterior LV process 4
• Intramural coronary venous mapping reveals fractionated electrograms 4
• PVC burden decreased from 18.7% to 2.8% (p<0.01) 4

For PACs with cardiomyopathy, the 2023 case report shows:

• Mapping identifies earliest atrial activation (commonly near pulmonary veins) 5
• Radiofrequency ablation successfully terminates PACs with normalized LV function on follow-up 5

Critical Caveats and Pitfalls

Pre-Ablation Evaluation Required:

1. Rule out structural heart disease - if ECG/echo don't clearly exclude it, obtain cardiac MRI 3
2. Assess LV function - echo to establish baseline LVEF
3. Document burden - 24-48 hour Holter to confirm >30% burden
4. ECG analysis - multifocal septal PVCs show PR >200ms (50%), QRS >100ms (75%), absent septal R waves (63%) 4

Risks to Discuss:

• Conduction system damage remains clinically relevant with septal ablation 4
• Malignant arrhythmia risk persists - 31% of multifocal septal PVC patients received appropriate ICD therapies despite ablation success 4
• Consider ICD evaluation if structural abnormalities found on MRI or intracardiac echo 4

Practical Algorithm

1. Immediate: Start beta-blocker (or calcium channel blocker if contraindicated)
2. Week 1-2: Obtain cardiac MRI if any suspicion of structural disease
3. Week 2-4: Reassess symptoms and repeat Holter
4. If burden remains >20-30% or symptoms persist: Refer for electrophysiology evaluation and catheter ablation
5. If LV dysfunction present: Expedite ablation referral (don't wait for medication trial)

The evidence strongly favors early ablation over prolonged medical management in high-burden cases like yours, given superior efficacy and the risk of developing irreversible cardiomyopathy 1, 3.